Assessment of MAO inhibitors using postmortem human brain tissue: biochemical and therapeutic implications.
D001921:Brain / Q000201:enzymology*; D004298:Dopamine / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D010627:Phenethylamines / Q000378:metabolism*; D012642:Selegiline / Q000494:pharmacology; D012701:Serotonin / Q000378:metabolism; D013237:Stereoisomerism; D014191:Tranylcypromine / Q000494:pharmacology
D008996:Monoamine Oxidase Inhibitors; D010627:Phenethylamines; D012642:Selegiline; C029261:phenethylamine; D012701:Serotonin; D014191:Tranylcypromine; D004298:Dopamine